Silvia Bettini

Dr. Silvia Bettini

Internal Medicine 3, Department of Medicine, DIMED, University of Padua
orcid
Medical Doctor, post degree in Internal Medicine, PhD in Cli...

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
LBLuca Busetto
Luca Busetto
SBSilvia Bettini
Silvia Bettini
JMJanine Makaronidis
Janine Makaronidis
CRCarl A. Roberts
Carl A. Roberts
JHJason C.G. Halford
Jason C.G. Halford
RBRachel L. Batterham
Rachel L. Batterham

5 August 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ABAnna Belligoli
Anna Belligoli
CCChiara Compagnin
Chiara Compagnin
MSMarta Sanna
Marta Sanna
FFFrancesca Favaretto
Francesca Favaretto
RFRoberto Fabris
Roberto Fabris
RVRoberto Vettor
Roberto Vettor
Although obesity represents a risk factor for the development of type 2 diabetes mellitus (T2DM), the link between these pathological conditions is not so clear. The manner in which the different elements of adipose tissue (AT) interplay in order to grow has been suggested to have a role in the genesis of metabolic complications, but this has not yet been fully addressed in humans. Through IHC, transmission electron microscopy, cytometry, and in vitro cultures, we described the morphological and functional changes of subcutaneous and visceral AT (SAT and VAT) in normoglycemic, prediabetic and T2DM patients with obesity compared to lean subjects. In both SAT and VAT we measured a hypertrophic and hyperplastic expansion, causing similar vascular rarefaction in obese patients with different degrees of metabolic complications. Capillaries display dysfunctional basement membrane thickening only in T2DM patients evidencing VAT as a new target of T2DM microangiopathy. The largest increase in adipocyte size and decrease in adipose stem cell number and adipogenic potential occur both in T2DM and in prediabetes. We showed that SAT and VAT remodeling with stemness deficit is associated with early glucose metabolism impairment suggesting the benefit of an AT-target therapy controlling hypertrophy and hyperplasia already in prediabetic obese patients.

13 July 2020 in Obesity Facts
Verified
Journal Article
Open access
PDF file
DDDror Dicker
Dror Dicker
SBSilvia Bettini
Silvia Bettini
NFNathalie Farpour-Lambert
Nathalie Farpour-Lambert
GFGema Frühbeck
Gema Frühbeck
RGRachel Golan
Rachel Golan
LBLuca Busetto
Luca Busetto
The World Health Organization declared COVID-19, the infectious disease caused by the coronavirus SARS-CoV-2, a pandemic on March 12, 2020. COVID-19 is causing massive health problems and economic suffering around the world. The European Association for the Study of Obesity (EASO) promptly recognised the impact that the outbreak could have on people with obesity. On one side, emerging data suggest that obesity represents a risk factor for a more serious and complicated course of COVID-19 in adults. On the other side, the health emergency caused by the outbreak diverts attention from the prevention and care of non-communicable chronic diseases to communicable diseases. This might be particularly true for obesity, a chronic and relapsing disease frequently neglected and linked to significant bias and stigmatization. The Obesity Management Task Force (OMTF) of EASO contributes in this paper to highlighting the key aspects of these two sides of the coin and suggests some specific actions.

12 March 2018 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
SBSilvia Bettini
Silvia Bettini
EBEmanuel Bordigato
Emanuel Bordigato
RFRoberto Fabris
Roberto Fabris
RSRoberto Serra
Roberto Serra
CPChiara Dal Pra’
Chiara Dal Pra’
Luca BusettoLuca Busetto
Luca Busetto

20 May 2023 in Current Obesity Reports
Verified
Journal Article
Open access
PDF file
VGValeria Guglielmi
Valeria Guglielmi
SBSilvia Bettini
Silvia Bettini
PSPaolo Sbraccia
Paolo Sbraccia
LBLuca Busetto
Luca Busetto
MPMassimo Pellegrini
Massimo Pellegrini
Giovanna MuscogiuriGiovanna Muscogiuri
Giovanna Muscogiuri
Purpose of Review: To highlight the added benefits of approved and upcoming, centrally-acting, anti-obesity drugs, focusing not only on the most common metabolic and cardiovascular effects but also on their less explored clinical benefits and drawbacks, in order to provide clinicians with a tool for more comprehensive, pharmacological management of obesity. Recent Findings: Obesity is increasingly prevalent worldwide and has become a challenge for healthcare systems and societies. Reduced life expectancy and cardiometabolic complications are some of the consequences of this complex disease. Recent insights into the pathophysiology of obesity have led to the development of several promising pharmacologic targets, so that even more effective drugs are on the horizon. The perspective of having a wider range of treatments increases the chance to personalize therapy. This primarily has the potential to take advantage of the long-term use of anti-obesity medication for safe, effective and sustainable weight loss, and to concomitantly address obesity complications/comorbidities when already established. Summary: The evolving scenario of the availability of anti-obesity drugs and the increasing knowledge of their added effects on obesity complications will allow clinicians to move into a new era of precision medicine.

29 October 2021 in Reviews in Endocrine and Metabolic Disorders
Verified
Journal Article
Open access
PDF file
FFFrancesca Favaretto
Francesca Favaretto
SBSilvia Bettini
Silvia Bettini
Luca BusettoLuca Busetto
Luca Busetto
GMGabriella Milan
Gabriella Milan
RVRoberto Vettor
Roberto Vettor
In physiological conditions, the adipose organ resides in well-defined areas, where it acts providing an energy supply and as an endocrine organ involved in the control of whole-body energy metabolism. Adipose tissue adipokines connect the body’s nutritional status to the regulation of energy balance. When it surrounds organs, it provides also for mechanical protection. Adipose tissue has a complex and heterogenous cellular composition that includes adipocytes, adipose tissue-derived stromal and stem cells (ASCs) which are mesenchymal stromal cells, and endothelial and immune cells, which signal to each other and to other tissues to maintain homeostasis. In obesity and in other nutrition related diseases, as well as in age-related diseases, biological and functional changes of adipose tissue give rise to several complications. Obesity triggers alterations of ASCs, impairing adipose tissue remodeling and adipose tissue function, which induces low-grade systemic inflammation, progressive insulin resistance and other metabolic disorders. Adipose tissue grows by hyperplasia recruiting new ASCs and by hypertrophy, up to its expandability limit. To overcome this limitation and to store the excess of nutrients, adipose tissue develops ectopically, involving organs such as muscle, bone marrow and the heart. The origin of ectopic adipose organ is not clearly elucidated, and a possible explanation lies in the stimulation of the adipogenic differentiation of mesenchymal precursor cells which normally differentiate toward a lineage specific for the organ in which they reside. The chronic exposition of these newly-formed adipose depots to the pathological environment, will confer to them all the phenotypic characteristics of a dysfunctional adipose tissue, perpetuating the organ alterations. Visceral fat, but also ectopic fat, either in the liver, muscle or heart, can increase the risk of developing insulin resistance, type 2 diabetes, and cardiovascular diseases. Being able to prevent and to target dysfunctional adipose tissue will avoid the progression towards the complications of obesity and other nutrition-related diseases. The aim of this review is to summarize some of the knowledge regarding the presence of adipose tissue in particular tissues (where it is not usually present), describing the composition of its adipogenic precursors, and the interactions responsible for the development of organ pathologies.